The Federal Trade Commission said yesterday that it plans to subpoena nearly 200 pharmaceutical companies as part of an investigation into possible anticompetitive practices in the prescription-drug industry.
The subpoenas, which require approval from the Office of Management and Budget, would form part of an investigation into whether pharmaceutical companies are stifling competition by releasing authorized generic copies of their own brand-name drugs to coincide with the introduction of generic challengers made by competitors.
The 190 subpoenas, including to 80 brand-name manufacturers, could go out late this summer, the FTC said.
A final report would be completed next year.
Source: WSJ
No comments:
Post a Comment